Natera Inc (Natera), formerly Gene Security Network LLC, develops genetic and cell-free deoxyribonucleic acid (cfDNA) testing solutions. The company’s products include Signatera, a personalized ctDNA (circulating tumor DNA) blood test to assess MRD (molecular residual disease) and its recurrence; Aletra, a tissue-based genomic profiling test to identify genomic alterations and oncology biomarkers in a tumor; Prospera, a transplant rejection test to evaluate the risk of rejection of a transplanted kidney. It also offers Renasight test to detect genetic cause of kidney diseases; Horizon carrier screening test; Panorama non-invasive prenatal screening test; Empower hereditary cancer test; Vistara prenatal single gene screening test; Anora miscarriage test; and Spectrum preimplantation genetic test. Natera is headquartered in Austin, Texas, the US.
Headquarters
United States of America
Address
13011 Mccallen Pass, Building A Suite 100, Austin, Texas, 78753
Website
www.natera.com
Telephone
1 650 2499090
No of Employees
2,670
Industry
Medical Equipment
Ticker Symbol & Exchange
NTRA (NASD)
Revenue (2021)
$625.5M
60%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
-105.3%
(2021 vs 2020)
Market Cap*
$3.4B
Net Profit Margin (2021)
XXX
-28.4%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| Signatera: | natera |
| Circulating Tumor DNA Blood Test | Signatera |
| Aletra: | Prospera |
| XXX | XXX |
| XXX | XXX |
| XXX | XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Others | In January, the company anounced its expansion into the early cancer detection (ECD) market to advance the company’s strategic growth objectives. |
| 2021 | New Products/Services | In June, the company and BGI Genomics announced to launch BGI/Natera Signatera Assay for biopharmaceutical customers and clinicians across China. |
| 2021 | New Product Approvals | In June, the company secured ADLT status from the Centers for Medicare & Medicaid Services for the Signatera molecular residual disease test. |
Competitor Comparison
| Key Parameters | Natera Inc | Roche Diagnostics International Ltd | Exact Sciences Corp | Guardant Health Inc | Adaptive Biotechnologies Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Austin | Rotkreuz | Madison | Redwood City | Seattle |
| State/Province | Texas | Zug | Wisconsin | California | Washington |
| No. of Employees | 2,670 | 2,600 | 6,420 | 1,373 | 858 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Matthew Rabinowitz, Ph.D. | Chairman | Executive Board | 2019 | 48 |
| Steve Chapman | Chief Executive Officer; President; Director | Executive Board | 2019 | 42 |
| Michael Brophy | Chief Financial Officer | Senior Management | 2017 | 41 |
| Robert Schueren | Chief Operating Officer | Senior Management | 2019 | 58 |
| Renee Genovese | Senior Director-Training | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer